Claudia Fox

52 statements · 2 topics · summaries given as host listed separately

Featured statements

These medications do not work in a vacuum. They help you adhere to your eating plan. If you don't have an eating plan, they do nothing.

quote · Pediatric Obesity

Severe obesity is defined as BMI greater than 1.2 times the 95th percentile.

guideline · Pediatric Obesity

Bupropion-naltrexone combination works by bupropion stimulating POMC cells to secrete alpha-MSH (which stimulates MC4 receptors to decrease hunger), while naltrexone blocks the auto-inhibitory feedback from beta-endorphin, allowing relatively more alpha-MSH activity.

clinical · Severe Obesity

In a study comparing inpatient (6 months) versus outpatient lifestyle modification therapy followed for 2 years, there was no statistically significant difference in outcomes at 2 years despite better response during inpatient treatment.

clinical · Severe Obesity

Nothing matches these filters — clear the search or widen the filters.

Claudia's statements about Pediatric Obesity 26 statements

Open the Pediatric Obesity collection →

Pharmacology: Pediatric Obesity 2017

Statement Of 12-year-olds with BMI at 99th percentile, all will grow up to have BMIs greater than 30, 88% will have BMIs greater than 35, and 2/3 will have class 3 obesity, according to the Bogalusa Heart Study. Open

Statement Severe obesity is defined as BMI greater than 1.2 times the 95th percentile. Open

Statement Only 2% of teenagers with severe obesity demonstrated clinically significant BMI reduction with lifestyle modification therapy. Open

Statement In a study comparing inpatient (6 months) versus outpatient lifestyle modification therapy followed for 2 years, there was no statistically significant difference in outcomes at 2 years despite better response during inpatient treatment. Open

Statement Mutations in the melanocortin 4 receptor (MC4R) account for the most common single gene mutation causing early onset severe obesity in pediatrics. Open

Statement Bupropion-naltrexone combination works by bupropion stimulating POMC cells to secrete alpha-MSH (which stimulates MC4 receptors to decrease hunger), while naltrexone blocks the auto-inhibitory feedback from beta-endorphin, allowing relatively more alpha-MSH activity. Open

Statement When people lose weight, they experience increased hunger, decreased satiety, increased preference for highly palatable foods, and increased metabolic efficiency—all promoting weight regain. Open

Statement Bariatric surgery is currently the most effective and durable treatment for severe obesity in adolescents. Open

Statement Orlistat is a lipase inhibitor that blocks absorption of about 30% of fat, is FDA approved for children 12 and older, and in the largest RCT of about 500 patients showed placebo-subtracted BMI difference of about 0.8 units at one year. Open

Statement Phentermine is FDA approved for age 16 and older (from 1950s approval), but there have been no RCTs in adolescents longer than 1 month duration. Open

Statement Among adults, phentermine produces mean weight loss of about 3.5 kg. Open

Statement In studies of adults on phentermine, there have been no withdrawal symptoms upon abruptly stopping and no reports of increased blood pressure, probably because patients are losing weight. Open

Statement In a chart review of 25 patients on phentermine only for 6 months plus lifestyle modification, compared to 274 receiving only lifestyle modification, there was about a 4% decrease in BMI favoring the phentermine group. Open

Statement After many studies of metformin, we can expect about a one unit decrease in BMI. Open

Statement Liraglutide, a GLP-1 agonist, has recently been FDA approved for obesity in adults. Open

Statement In a pilot study of exenatide (GLP-1 agonist) with about 25 patients, during the first 3 months double-blinded portion, there was a placebo-subtracted effect of about 3% in BMI favoring the exenatide group. Open

Statement In a chart review of patients taking topiramate only (no other medications) with lifestyle modification therapy, there was about a 6% decrease in BMI at 6 months. Open

Statement In an RCT of topiramate 75mg/day after meal replacement induction phase, there was no statistically significant effect between topiramate and placebo groups by study end. Open

Statement Topiramate is FDA approved down to age 2 for seizures and has been used in pediatrics for decades. Open

Statement Topiramate at 75mg/day was safe in adolescents, with extensive neurocognitive testing showing no signal of cognitive deficits. Open

Quotation These medications do not work in a vacuum. They help you adhere to your eating plan. If you don't have an eating plan, they do nothing. Open

Statement Early success in weight management predicts long-term weight loss success, according to adult literature. Open

Statement Obesity is a chronic disease requiring indefinite medication treatment; stopping the medication results in weight regain, similar to stopping antihypertensive medication causing blood pressure to rise. Open

Quotation You don't develop dependence on it, you don't rely on it, any more than you would develop a reliance on an antihypertensive agent to treat your high blood pressure. Open

Statement Bariatric surgery is seen as more acceptable than pharmacotherapy for pediatric obesity, despite being arguably riskier and irreversible. Open

Statement Recently FDA-approved medications for adult obesity (age 18+) include topiramate-phentermine combination, liraglutide, naltrexone-bupropion combination, and lorcaserin, approved for BMI >30 or >27 with weight-related comorbidities. Open

Claudia's statements about Severe Obesity 26 statements

Open the Severe Obesity collection →